20Jul
Read more...
06May
Precision Biologics, Inc. CEO Philip M Arlen to give Keynote at 7th Ace Drug Discovery Summit, San Diego, CA
Precision Biologics, Inc. CEO Philip M Arlen, MD, will give a Keynote speech and present...
19Apr
AACR 2026 Annual Meeting, San Diego, CA April 19, 2026
NEO-201-recognized truncated Car 1 O-glycans represent a new target for CAR-NK therapy in AML
17Apr
Precision Biologics mentioned in Article in Business News Today April 17, 2026
Precision Biologics has revealed a new AML CAR-NK target at AACR 2026. Read why truncated...
17Apr
Precision Biologics’ Collaborators at NHLBI/NIH and U Va to Reveal New AML Target for CAR-NK at American Association for Cancer Research (AACR) Annual Meeting on April 19th, 2026, San Diego, CA
Truncated Core 1 O-glycans recognized by Precision Biologics’ monoclonal antibody (mAb) NEO-201 are discovered as...
17Apr
Precision Biologics Highlights New AML Target for CAR-NK Therapies
US-based Precision Biologics, a clinical stage biotechnology company, has announced new preclinical findings identifying a...
12Mar
Precision Biologics, Inc. CEO to present at the online Antibody-Drug Conjugates MicroSummit conference, March 17th, 2026.
Philip M. Arlen, M.D., will present an online talk at the third and last session...
08Mar
Precision Biologics featured in Pharma Device News article March 8, 2026
Precision Biologics' approach is the subject of an article in the current issue of trade...
02Mar
Precision Biologics, Inc. CEO Philip M. Arlen, MD, to give presentation on monoclonal antibodies against tumor-specific targets at Festival of Biologics USA, San Diego Convention Center, San Diego, CA, March 4-5, 2026
Precision Biologics, Inc. CEO Philip M. Arlen, MD, will give a presentation on monoclonal antibodies...
17Feb
Dr. Philip M Arlen to present Keynote at the 6th Ace Drug Discovery Summit, London, UK, February 19, 2026
Precision Biologics, Inc. CEO Philip M Arlen, MD will give a Keynote speech and present...